News | March 02, 2022
USFDA issues new clinical trial guidelines for cancer treatments
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
110 BDS graduates admitted in week one of the launch
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
Subscribe To Our Newsletter & Stay Updated
